Moderate hypofractionated radiotherapy for prostate cancer: 3-year toxicity results of a multicentre randomized phase 3, non-inferiority trial

V. Fonteyne,C. Berghen,C. Van Praet,B. Vanderstraeten,S. Verbeke,G. Villeirs,R. Colman,B. Vanneste,P. Ost,G. De Meerleer,N. Lumen

DOI: https://doi.org/10.1016/j.radonc.2024.110089

IF: 6.901

2024-01-26

Radiotherapy and Oncology

Abstract:Background and purpose Moderate hypofractionated radiotherapy (HFRT) is a standard treatment for prostate cancer patients. We compared 2 moderate HFRT regimens, with a biologically equivalent dose of 80 Gy in 2 Gy fractions, with a modest simultaneous integrated boost to the dominant intraprostatic lesion. Material and methods This is a multicenter, non-inferiority, randomized phase 3 trial with acute toxicity as the primary endpoint, comparing: - 56Gy in 4 weeks (16x3.5Gy, 4 days/week, Arm A). - 67Gy in 5 weeks (25x2.68Gy, 5 days/week, Arm B). The H0 hypothesis is that both regimens are equivalent in terms of acute grade≥2 gastro-intestinal toxicity, defined as a difference in acute grade≥2 gastro-intestinal toxicity of ≤10%. Here we report on acute and late toxicity. Results We included 170 patients in Arm A and 172 patients in Arm B. The median follow-up time for all patients was 42 months. Acute grade≥2 gastrointestinal toxicity was reported by 24% of patients in both groups. Acute grade 2 and 3 urinary toxicity was observed in 52% and 9% of patients in Arm A and 53% and 7% in Arm B. Late grade 2 and grade≥3 gastrointestinal toxicity occurred in 19% and 4% of patients in Arm A compared with 15% and 4% in Arm B. Late grade 2 and grade≥3 urinary toxicity was observed in 37% and 10% of patients in Arm A and 36% and 6% in Arm B. Conclusion This analysis confirms that both HFRT regimens are safe and equivalent in terms of acute grade≥2 gastrointestinal toxicity.

oncology,radiology, nuclear medicine & medical imaging